These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. Al Hadidi S; Schinke C; Thanendrarajan S; Zangari M; van Rhee F JAMA Netw Open; 2022 Apr; 5(4):e228161. PubMed ID: 35442451 [TBL] [Abstract][Full Text] [Related]
65. Current and Future Status of Diversity in Ophthalmologist Workforce. Xierali IM; Nivet MA; Wilson MR JAMA Ophthalmol; 2016 Sep; 134(9):1016-23. PubMed ID: 27416525 [TBL] [Abstract][Full Text] [Related]
66. Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015. Chen A; Wright H; Itana H; Elahi M; Igun A; Soon G; Pariser AR; Fadiran EO J Womens Health (Larchmt); 2018 Apr; 27(4):418-429. PubMed ID: 29048983 [TBL] [Abstract][Full Text] [Related]
67. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013. Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506 [TBL] [Abstract][Full Text] [Related]
68. Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers. Wagar MK; Mojdehbakhsh RP; Godecker A; Rice LW; Barroilhet L Gynecol Oncol; 2022 Apr; 165(1):49-52. PubMed ID: 35144798 [TBL] [Abstract][Full Text] [Related]
69. Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of Multiple Sclerosis DMTs: A Systematic Review. Onuorah HM; Charron O; Meltzer E; Montague A; Crispino A; Largent A; Lucas A; Freeman L Neurology; 2022 Mar; 98(9):e880-e892. PubMed ID: 35046135 [TBL] [Abstract][Full Text] [Related]
70. Underreporting and Underrepresentation of Race and Ethnicity in Head and Neck Cancer Trials, 2010-2020: A Systematic Review. Sauer AB; Daher GS; Lohse CM; Glasgow AE; Habermann EB; Douse DM; Moore EJ; Ighodaro ET; Van Abel KM; Yin LX JAMA Otolaryngol Head Neck Surg; 2022 Jul; 148(7):662-669. PubMed ID: 35653143 [TBL] [Abstract][Full Text] [Related]
71. Temporal trends and characteristics associated with racial, ethnic, and sex representation in COVID-19 clinical trials: A systematic review and meta-analysis. Kaczynski M; Vassilopoulos A; Vassilopoulos S; Sisti A; Benitez G; Tran QL; Mylona EK; Shehadeh F; Rogers R; Mylonakis E Contemp Clin Trials; 2024 Aug; 143():107578. PubMed ID: 38789079 [TBL] [Abstract][Full Text] [Related]
72. New Drug Formulary Management and Utilization: Evidence in Sex, Race, and Ethnicity: 2019-2020. Keeys CA; Harding BW; Migneco GE; Rahini SS; Coleman HB Ann Pharmacother; 2022 Feb; 56(2):139-145. PubMed ID: 34049437 [TBL] [Abstract][Full Text] [Related]
73. Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor Trials. Riaz IB; Islam M; Khan AM; Naqvi SAA; Siddiqi R; Khakwani KZR; Asghar N; Ikram W; Hussain SA; Singh P; Warner JL; Sonpavde GP; Odedina FT; Kehl KL; Duma N; Bryce AH Am J Med; 2022 Aug; 135(8):984-992.e6. PubMed ID: 35483426 [TBL] [Abstract][Full Text] [Related]
74. Longitudinal Trends and Disparities in Diabetic Retinopathy Within an Aggregate Health Care Network. Markle J; Shaia JK; Araich H; Sharma N; Talcott KE; Singh RP JAMA Ophthalmol; 2024 Jul; 142(7):599-606. PubMed ID: 38869883 [TBL] [Abstract][Full Text] [Related]
75. Race and ethnic representation among clinical trials for diabetic retinopathy and diabetic macular edema within the United States: A review. Sanjiv N; Osathanugrah P; Harrell M; Siegel NH; Ness S; Chen X; Cabral H; Subramanian ML J Natl Med Assoc; 2022 Apr; 114(2):123-140. PubMed ID: 35078668 [TBL] [Abstract][Full Text] [Related]
76. New Benchmarks on Demographic Disparities in Pivotal Trials Supporting FDA-Approved Drugs and Biologics. Smith Z; Botto E; Johnson O; Rudo T; Getz K Ther Innov Regul Sci; 2024 Jan; 58(1):143-152. PubMed ID: 37775684 [TBL] [Abstract][Full Text] [Related]
77. Diversity, Equity, and Inclusion in Urolithiasis Clinical Trials: Representative Enrollment by Race, Ethnicity, and Sex. Reed AM; Hsi RS Urol Pract; 2024 Jul; 11(4):685-691. PubMed ID: 38899669 [TBL] [Abstract][Full Text] [Related]
78. Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration. Hilal T; Gonzalez-Velez M; Prasad V JAMA Intern Med; 2020 Aug; 180(8):1108-1115. PubMed ID: 32539071 [TBL] [Abstract][Full Text] [Related]
79. Diversity of Participation in Clinical Trials and Influencing Factors: Findings from the Health Information National Trends Survey 2020. Walker DM; Swoboda CM; Shiu-Yee K; Tarver WL; Nolan TS; Joseph JJ J Gen Intern Med; 2023 Mar; 38(4):961-969. PubMed ID: 36138277 [TBL] [Abstract][Full Text] [Related]
80. A Cross-Sectional Study of Sex, Race, and Ethnic Representation in Burn Registered Clinical Trials. Sheikh-Oleslami S; Tao B; Papp B; Luthra S; Papp A J Racial Ethn Health Disparities; 2023 Dec; ():. PubMed ID: 38148442 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]